TapImmune Inc. Stock OTC Bulletin Board
Stocks
US8760332002
Biotechnology & Medical Research
|
End-of-day quote
OTC Bulletin Board
|
||
| - USD | - |
|
| Market Cap | 20.34M 17.85M 16.78M 15.34M 28.67M 1.95B 28.88M 202M 78.15M 993M 76.39M 74.71M 3.22B | P/E 2026 * |
-2.06x | P/E 2027 * | -1.39x |
|---|---|---|---|---|---|
| Enterprise Value | 20.34M 17.85M 16.78M 15.34M 28.67M 1.95B 28.88M 202M 78.15M 993M 76.39M 74.71M 3.22B | EV / Sales 2026 * |
4.8x | EV / Sales 2027 * | 1.01x |
| Free-Float |
94.51% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: TapImmune Inc.
| 20/08/21 | Wall Street hoger gesloten | |
| 20/08/21 | Wall Street koerst af op hoger slot | |
| 20/08/21 | Wall Street richting lagere opening |
| Manager | Title | Age | Since |
|---|---|---|---|
Juan Vera
CEO | Chief Executive Officer | 46 | 01/05/2023 |
| Chief Operating Officer | 36 | 01/12/2023 | |
Patricia Allison
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Juan Vera
BRD | Director/Board Member | 46 | 17/10/2018 |
Norman Eansor
CHM | Chairman | 65 | 24/05/2022 |
Steven Elms
BRD | Director/Board Member | 62 | 06/08/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.18% | +4.35% | +4.23% | +30.02% | 47.86B | |
| -0.78% | +0.00% | +44.18% | +32.83% | 44.46B | |
| -1.36% | +4.19% | +10.20% | +90.49% | 41.85B | |
| -1.27% | -2.92% | +330.25% | +544.71% | 41.34B | |
| -0.62% | -0.06% | +10.15% | +46.02% | 30.04B | |
| -1.95% | +0.44% | +24.79% | +153.02% | 17.59B | |
| -6.57% | -9.98% | - | - | 15.6B | |
| -3.55% | +1.95% | +21.97% | +39.13% | 15.69B | |
| -1.45% | +8.75% | -9.55% | - | 13.93B | |
| Average | -1.95% | +2.66% | +54.53% | +133.74% | 29.82B | |
| Weighted average by Cap. | -1.43% | +1.88% | +68.04% | +141.89% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 4.24M 3.72M 3.5M 3.2M 5.98M 406M 6.02M 42.04M 16.3M 207M 15.93M 15.58M 672M | 20.19M 17.72M 16.65M 15.23M 28.45M 1.93B 28.66M 200M 77.55M 986M 75.8M 74.14M 3.2B |
| Net income | -11.84M -10.39M -9.77M -8.93M -16.68M -1.13B -16.81M -117M -45.47M -578M -44.45M -43.47M -1.87B | -18.09M -15.88M -14.93M -13.65M -25.5M -1.73B -25.69M -179M -69.5M -884M -67.94M -66.45M -2.86B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
